Heart failure with preserved ejection fraction: how can we approach it?

Revista de la Facultad de Ciencias de la Salud de la Universidad del Cauca

View Publication Info
 
 
Field Value
 
Title Heart failure with preserved ejection fraction: how can we approach it?
Insuficiencia cardiaca con fracción de eyección conservada: ¿Cómo podemos abordarla?
 
Creator Orozco-Burbano, Juan David
Cabrera-Velasco, Carlos Ernesto
Ortiz-Andrade, Juan Isaac
López-Garzón, Nelson Adolfo
 
Subject Heart failure
Ejection fraction
Biomarkers
Phenotype
Treatment
Insuficiencia Cardíaca
Fracción de eyección
Biomarcadores
Fenotipo
Tratamiento
 
Description Heart failure with preserved ejection fraction (ICFEp) is a syndrome with a prevalence of 1 - 5.5% that is associated with old age and various inflammatory and metabolic mechanisms that trigger structural alterations that result in characteristic signs and symptoms. Diagnosis is made with clinical characteristics and echocardiographic study, and despite its implication in the mortality of the affected individuals, there are no effective measures to reduce adverse effects, so the management is oriented to each comorbidity, and It has even been proposed to take the therapy towards subgroups with defined characteristics. For this review, a bibliographic search on different databases was carried out, prioritizing information obtained from randomized studies and meta-analysis.
Resumen
La insuficiencia cardiaca con fracción de eyección preservada (ICFEp) constituye un síndrome con una prevalencia de 1 - 5.5 % que se asocia a edad avanzada y para el cual se han identificado diversos mecanismos inflamatorios y metabólicos que desencadenan las alteraciones estructurales que la caracterizan y a su vez resultan en signos y síntomas característicos.  Para su diagnóstico se deben reunir características clínicas con el estudio ecocardiogragico, y pese a su implicación en la mortalidad de los individuos afectados, en la actualidad no se dispone de medidas efectivas para disminuir adversos por lo que se suele dar manejo a cada comorbilidad, e incluso se ha postulado orientar la terapia hacia subgrupos con características definidas. Para la  presente revisión de tema se realizó una revisión bibliográfica de diferentes bases de datos priorizando información obtenida en estudios aleatorizados y meta-análisis
 
 
Publisher Universidad del Cauca
 
Date 2020-07-01
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
 
Format application/pdf
 
Identifier https://revistas.unicauca.edu.co/index.php/rfcs/article/view/1489
10.47373/rfcs.2020.v22.1489
 
Source Revista de la Facultad de Ciencias de la Salud Universidad del Cauca; Vol. 22 No. 2 (2020): Colecistectomía laparoscópica; 26-33
Revista de la Facultad de Ciencias de la Salud Universidad del Cauca; Vol. 22 Núm. 2 (2020): Colecistectomía laparoscópica; 26-33
2538-9971
0124-308X
 
Language spa
 
Relation https://revistas.unicauca.edu.co/index.php/rfcs/article/view/1489/1378
/*ref*/Redfield M. Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine. 2016;375(19):1868-1877. 2. Ponikowski P, Voors A, Anker S, Bueno H, Cleland J, Coats A et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure. 2016;18(8):891-975. 3. Oktay A, Shah S. Diagnosis and Management of Heart Failure with Preserved Ejection Fraction: 10 Key Lessons. Current Cardiology Reviews. 2014;11(1):42-52. 4. Oktay A, Rich J, Shah S. The Emerging Epidemic of Heart Failure with Preserved Ejection Fraction. Current Heart Failure Reports. 2013;10(4):401-410. 5. Gómez E. Identificación de pacientes con falla cardiaca y función sistólica preservada: Un estudio epidemiológico regional (I-PREFER Study) – Colombia. Revista Colombiana de Cardiología. 2013;20(2):58-67. 6. Tibrewala A, Yancy C. Heart Failure with Preserved Ejection Fraction in Women. Heart Failure Clinics. 2019;15(1):9-18. 7. Tromp J, MacDonald M, Tay W, Teng T, Hung C, Narasimhan C et al. Heart Failure With Preserved Ejection Fraction in the Young. Circulation. 2018;138(24):2763-2773. 8. Gupta D, Shah A, Castagno D, Takeuchi M, Loehr L, Fox E et al. Heart Failure With Preserved Ejection Fraction in African Americans. JACC: Heart Failure. 2013;1(2):156-163. 9. Lai Y, Wang L, Gladwin M. Insights into the Pulmonary Vascular complications of heart failure with Preserved Ejection Fraction. The Journal of Physiology. 2018;. 10. Borlaug B. The pathophysiology of heart failure with preserved ejection fraction. Nature Reviews Cardiology. 2014;11(9):507-515. 11. Cikes M, Claggett B, Shah A, Desai A, Lewis E, Shah S et al. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure. 2018;6(8):689-697. 12. Vaduganathan M, Patel R, Michel A, Shah S, Senni M, Gheorghiade M et al. Mode of Death in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology. 2017;69(5):556-569. 13. Zile M, Litwin S. Heart Failure with a Preserved Ejection Fraction. En: Zipes D, Libby P, Bonow R, Mann D, Tomaselli G. Editors. Braunwald heart disease a textbooks of cardiovascular medicine. Eleventh edition. Philadelphia: ELSEVIER; 2019. P. 1287-1344 14. Lam C, Voors A, de Boer R, Solomon S, van Veldhuisen D. Heart failure with preserved ejection fraction: from mechanisms to therapies. European Heart Journal. 2018;39(30):2780-2792. 15. Meijers W, van der Velde A, de Boer R. Biomarkers in heart failure with preserved ejection fraction. Netherlands Heart Journal. 2016;24(4):252-258. 16. Iwano H, Little W. Heart failure: What does ejection fraction have to do with it?. Journal of Cardiology. 2013;62(1):1-3. 17. Mentz R, Kelly J, von Lueder T, Voors A, Lam C, Cowie M et al. Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction. Journal of the American College of Cardiology. 2014;64(21):2281-2293. 18. Hegde S, Claggett B, Shah A, Lewis E, Anand I, Shah S et al. Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist). Circulation. 2017;136(11):982-992. 19. Pandey A, Parashar A, Kumbhani D, Agarwal S, Garg J, Kitzman D et al. Exercise Training in Patients With Heart Failure and Preserved Ejection Fraction. Circulation: Heart Failure. 2015;8(1):33-40. 20. Shah S, Kitzman D, Borlaug B, van Heerebeek L, Zile M, Kass D et al. Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction. Circulation. 2016;134(1):73-90. 21. Pandey A, Patel K, Vaduganathan M, Sarma S, Haykowsky M, Berry J et al. Physical Activity, Fitness, and Obesity in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure. 2018;6(12):975-982. 22. Yancy C, Jessup M, Bozkurt B, Butler J, Casey D, Drazner M et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation. 2013;128(16). 23. de Denus S, O’Meara E, Desai A, Claggett B, Lewis E, Leclair G et al. Spironolactone Metabolites in TOPCAT — New Insights into Regional Variation. New England Journal of Medicine. 2017;376(17):1690-1692. 24. Zheng S, Chan F, Nabeebaccus A, Shah A, McDonagh T, Okonko D et al. Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart. 2017;104(5):407-415. 25. Martin N, Manoharan K, Thomas J, Davies C, Lumbers R. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database of Systematic Reviews. 2018;. 26. Bavishi C, Chatterjee S, Ather S, Patel D, Messerli F. Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis. Heart Failure Reviews. 2014;20(2):193-201. 27. Solomon Scott, Mc Murray John, E et al. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction- PARAGON HF The NEJM 2019 ; September 1: Pag1-11. 28. Sueta Daisuki, Yamamoto Eiichiro, et al. H2FPEF Score as a Prognostic Value in HFpEF patients. American Journal of Hypertension, 2019: Pag 1-37
 
Rights Derechos de autor 2020 Universidad del Cauca
info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/4.0
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library